View Future GrowthAmicogen 過去の業績過去 基準チェック /06Amicogenの収益は年間平均-46.3%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間18.6% 0.6%割合で 減少しています。主要情報-46.28%収益成長率-42.50%EPS成長率Biotechs 業界の成長11.70%収益成長率-0.64%株主資本利益率-28.51%ネット・マージン-71.36%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Mar 25Full year 2024 earnings released: ₩961 loss per share (vs ₩584 loss in FY 2023)Full year 2024 results: ₩961 loss per share (further deteriorated from ₩584 loss in FY 2023). Revenue: ₩173.6b (up 8.6% from FY 2023). Net loss: ₩52.8b (loss widened 127% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.分析記事 • Dec 30Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...すべての更新を表示Recent updatesお知らせ • Mar 11Amicogen, Inc., Annual General Meeting, Mar 31, 2026Amicogen, Inc., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 33, yeongudanji-ro 55beon-gil, yeonsu-gu, incheon South KoreaNew Risk • Feb 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (₩87.7b market cap, or US$61.5m).New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩69.6b market cap, or US$48.2m).お知らせ • Feb 10Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion.Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,925,374 Price\Range: KRW 1164分析記事 • Dec 22Investors Don't See Light At End Of Amicogen, Inc.'s (KOSDAQ:092040) Tunnel And Push Stock Down 33%Unfortunately for some shareholders, the Amicogen, Inc. ( KOSDAQ:092040 ) share price has dived 33% in the last thirty...New Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 52% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩108.0b market cap, or US$73.0m).お知らせ • Dec 20Amicogen, Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.000002 billion.Amicogen, Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.000002 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,925,374 Price\Range: KRW 2010New Risk • Dec 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩143.8b (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩44b free cash flow). Earnings have declined by 52% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩143.8b market cap, or US$97.9m).New Risk • Nov 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩44b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩44b free cash flow). Earnings have declined by 52% per year over the past 5 years.分析記事 • Sep 08The Market Doesn't Like What It Sees From Amicogen, Inc.'s (KOSDAQ:092040) Revenues YetWith a price-to-sales (or "P/S") ratio of 1.8x Amicogen, Inc. ( KOSDAQ:092040 ) may be sending very bullish signals at...お知らせ • Aug 12Amicogen, Inc. announced that it has received KRW 7 billion in funding from BIFIDO Co., Ltd.On August 11, 2025, Amicogen, Inc. closed the transaction.New Risk • Jul 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 46% per year over the past 5 years.分析記事 • May 23Amicogen, Inc.'s (KOSDAQ:092040) Share Price Is Matching Sentiment Around Its RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.3x Amicogen, Inc. ( KOSDAQ:092040 ) is definitely a...Reported Earnings • Mar 25Full year 2024 earnings released: ₩961 loss per share (vs ₩584 loss in FY 2023)Full year 2024 results: ₩961 loss per share (further deteriorated from ₩584 loss in FY 2023). Revenue: ₩173.6b (up 8.6% from FY 2023). Net loss: ₩52.8b (loss widened 127% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 12Amicogen, Inc., Annual General Meeting, Mar 27, 2025Amicogen, Inc., Annual General Meeting, Mar 27, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 33, yeongudanji-ro 55beon-gil, yeonsu-gu, incheon South Korea分析記事 • Feb 17Is Amicogen (KOSDAQ:092040) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Jan 08Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 35%Amicogen, Inc. ( KOSDAQ:092040 ) shareholders are no doubt pleased to see that the share price has bounced 35% in the...New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding).お知らせ • Dec 12An undisclosed buyer agreed to acquire an unknown stake in Amicogen (China) Biopharm Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 54.7 billion.An undisclosed buyer agreed to acquire an unknown stake in Amicogen (China) Biopharm Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 54.7 billion on December 10, 2024. After completion of this ransaction, Amicogen, Inc. will hold 14.36% stake in Amicogen (China) Biopharm. Amicogen (China) Biopharm reported total assets of KRW 210.359 billion, total debt of KRW 95.656 billion, sales of KRW 84.911 billion and net income of KRW 8.074 billion as at September 30, 2024. The expected completion of the transaction is December 30, 2024.New Risk • Dec 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 3.7% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (40% increase in shares outstanding).New Risk • Dec 07New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (40% increase in shares outstanding).お知らせ • Nov 23Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040).Enzynomics Co., Ltd. agreed to acquire 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 5.6 billion on November 15, 2024. A cash consideration of KRW 5.6 billion will be paid by Enzynomics for 2,360,714 shares. For the period ending December 31, 2023, SKINMED Co., Ltd. reported total revenue of KRW 6.07 billion and net loss of KRW 1.04 billion. As of December 31, 2023, SKINMED Co., Ltd. reported total debt of KRW 4.96 billion, total assets of KRW 11.22 billion and total common equity of KRW 6.26 billion. Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) on November 19, 2024.分析記事 • Nov 11Revenues Working Against Amicogen, Inc.'s (KOSDAQ:092040) Share PriceAmicogen, Inc.'s ( KOSDAQ:092040 ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a strong buy right...お知らせ • Oct 30+ 1 more updateAmicogen, Inc. announced that it has received KRW 4 billion in funding from Kiwoom Securities Co., Ltd.On October 29, 2024 Amicogen, Inc. closed the transaction.New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding).分析記事 • Jun 27Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% PoundingTo the annoyance of some shareholders, Amicogen, Inc. ( KOSDAQ:092040 ) shares are down a considerable 27% in the last...分析記事 • Jun 19Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...分析記事 • Mar 21Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%Amicogen, Inc. ( KOSDAQ:092040 ) shares have had a really impressive month, gaining 39% after a shaky period...New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (39% increase in shares outstanding).New Risk • Dec 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 39% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (39% increase in shares outstanding).New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 44% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).お知らせ • Jul 19+ 1 more updateAmicogen, Inc. announced that it expects to receive KRW 40 billion in fundingAmicogen, Inc. announced a private placement of series 3 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 40,000,000,000 on July 18, 2022. The bonds will mature on July 20, 2027. The bonds are convertible into 1,622,520 common shares at a price of KRW 24,653 per share. The conversion period is from July 20, 2023 to June 20, 2027. The payment date is July 20, 2022. The transaction has been approved by the board of directors.Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩24,850, the stock trades at a trailing P/E ratio of 14.6x. Average trailing P/E is 33x in the Biotechs industry in South Korea. Total loss to shareholders of 34% over the past three years.お知らせ • Sep 03Amicogen, Inc. announced that it has received KRW 22.2724863 billion in funding from Lysando AGOn September 2, 2021, Amicogen, Inc. closed the transaction.お知らせ • Jul 23Amicogen, Inc. (KOSDAQ:A092040) agreed to acquire a 30% stake in BIFIDO Co., Ltd (KOSDAQ:A238200) from a group of shareholders for KRW 60.1 billion.Amicogen, Inc. (KOSDAQ:A092040) agreed to acquire a 30% stake in BIFIDO Co., Ltd (KOSDAQ:A238200) from a group of shareholders for KRW 60.1 billion on July 21, 2021. Under the term, Amicogen will acquire 2.45 million shares of BIFIDO at KRW 24,500 per shares. Amicogen will pay 20% of the consideration amounting to KRW 12.02 billion on July 21, 2021 as the down payment or first payment, second payment or the interim payment which is 30% of the consideration amounting to KRW 18.04 billion will be paid on August 20, 2021 and the balance which is 50% of the consideration amounting to KRW 30.06 billion will be paid on October 20, 2021. Post completion, Amicogen will hold 30% stake in BIFIDO. The transaction was resolved by the board of directors of Amicogen on July 21, 2021. The transaction is expected to close on October 21, 2021.お知らせ • Jul 15Amicogen, Inc. announced that it expects to receive KRW 22.2724863 billion in funding from Lysando AGAmicogen, Inc. announced a private placement of 532,198 shares at a price of KRW 41,850 per share for gross proceeds of KRW 22,272,486,300 on July 14, 2021. The transaction will include participation from Lysando AG. The transaction is expected to close on August 20, 2021. The securities to be issued will have a hold period of 1 year. The transaction was approved by the board of directors of the company. The company will received funding through third party allocation.お知らせ • Jul 01Amicogen, Inc. announced that it has received KRW 50 billion in fundingOn June 29, 2021, Amicogen, Inc. closed the transaction.お知らせ • Jun 24Amicogen, Inc. announced that it expects to receive KRW 50 billion in funding from Samsung Securities Co., Ltd. and other investorsAmicogen, Inc. (KOSDAQ:A092040) announced a private placement of series 1 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 50,000,000,000 on June 23, 2021. The transaction will include participation from Samsung Securities Co., Ltd. (KOSE:A016360) for KRW 46,000,000,000, and Small and Medium Business Banks for the rest. The bonds will mature on June 28, 2026. The bonds are convertible into 1,203,311 common shares at a price of KRW 41,552 per share. The conversion period is from June 29, 2022 to May 29, 2026. The payment date is June 29, 2021. The transaction has been approved by the board.分析記事 • Mar 23With EPS Growth And More, Amicogen (KOSDAQ:092040) Is InterestingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩36,300, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 54x in the Biotechs industry in South Korea. Total returns to shareholders of 7.7% over the past three years.分析記事 • Mar 05Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?Amicogen, Inc. ( KOSDAQ:092040 ) shareholders might be concerned after seeing the share price drop 14% in the last...Is New 90 Day High Low • Feb 24New 90-day low: ₩29,700The company is down 11% from its price of ₩33,400 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.分析記事 • Feb 15Is Amicogen (KOSDAQ:092040) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Feb 08New 90-day low: ₩31,700The company is down 5.0% from its price of ₩33,300 on 10 November 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period.分析記事 • Jan 31What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?Every investor in Amicogen, Inc. ( KOSDAQ:092040 ) should be aware of the most powerful shareholder groups...分析記事 • Jan 14Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?Amicogen (KOSDAQ:092040) has had a rough three months with its share price down 5.7%. However, stock prices are usually...分析記事 • Dec 30Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩38,400, the stock is trading at a trailing P/E ratio of 22.1x, up from the previous P/E ratio of 19.2x. This compares to an average P/E of 56x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 68%.分析記事 • Dec 15Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...分析記事 • Nov 30Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?While Amicogen, Inc. (KOSDAQ:092040) shareholders are probably generally happy, the stock hasn't had particularly good...収支内訳Amicogen の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A092040 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Dec 2541,981-29,96010,0797,44630 Sep 2587,966-63,42819,6158,90630 Jun 25117,721-49,63326,9749,76631 Mar 25150,247-52,96033,96311,10131 Dec 24173,605-52,79141,08812,60830 Sep 24155,739-35,70238,27212,63330 Jun 24158,984-36,90736,52213,36631 Mar 24155,881-30,70935,42213,21331 Dec 23159,904-23,28934,79913,78330 Sep 23164,246-29,42034,03814,51930 Jun 23160,012-28,64634,25614,04131 Mar 23152,966-36,63633,29913,67831 Dec 22144,296-47,22033,59612,43630 Sep 22139,504-39,81334,25811,64130 Jun 22124,834-61,07233,19611,85931 Mar 22123,766-3,13233,89611,54931 Dec 21124,8813,73333,79010,84330 Sep 21117,31733,20232,5089,72930 Jun 21122,41461,56932,0058,11131 Mar 21121,27439,19331,3416,75631 Dec 20115,85631,60431,1386,28230 Sep 20129,17133,39443,8205,02630 Jun 20120,53614,27243,1685,13231 Mar 20114,651-34,07443,8385,48731 Dec 19115,1818741,8215,37630 Sep 1990,8829,72825,6825,52430 Jun 1994,62021,42824,6675,24431 Mar 1991,33863,86721,5825,24531 Dec 1894,52240,16820,3125,18330 Sep 1899,01315,83419,4475,83230 Jun 1889,82214,60317,7825,56331 Mar 1886,089-3,39516,3655,12331 Dec 1773,665-4,60615,6244,77030 Sep 1772,07553315,9143,44030 Jun 1767,59433215,5223,18731 Mar 1766,193-62614,9842,63331 Dec 1668,9681,58914,2772,81130 Sep 1664,7821,63012,8993,10930 Jun 1657,4172,09811,7142,50431 Mar 1646,3543,2489,3432,47631 Dec 1532,4572,0666,3052,28830 Sep 1524,2634,8164,2671,67930 Jun 1526,6196,7743,2721,679質の高い収益: A092040は現在利益が出ていません。利益率の向上: A092040は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A092040は利益が出ておらず、過去 5 年間で損失は年間46.3%の割合で増加しています。成長の加速: A092040の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: A092040は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 32.2% ) と比較することは困難です。株主資本利益率高いROE: A092040は現在利益が出ていないため、自己資本利益率 ( -28.51% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 14:55終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Amicogen, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関So-Eun ChoiLS Securities Co., Ltd.
Reported Earnings • Mar 25Full year 2024 earnings released: ₩961 loss per share (vs ₩584 loss in FY 2023)Full year 2024 results: ₩961 loss per share (further deteriorated from ₩584 loss in FY 2023). Revenue: ₩173.6b (up 8.6% from FY 2023). Net loss: ₩52.8b (loss widened 127% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.
分析記事 • Dec 30Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...
お知らせ • Mar 11Amicogen, Inc., Annual General Meeting, Mar 31, 2026Amicogen, Inc., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 33, yeongudanji-ro 55beon-gil, yeonsu-gu, incheon South Korea
New Risk • Feb 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (₩87.7b market cap, or US$61.5m).
New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩69.6b market cap, or US$48.2m).
お知らせ • Feb 10Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion.Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,925,374 Price\Range: KRW 1164
分析記事 • Dec 22Investors Don't See Light At End Of Amicogen, Inc.'s (KOSDAQ:092040) Tunnel And Push Stock Down 33%Unfortunately for some shareholders, the Amicogen, Inc. ( KOSDAQ:092040 ) share price has dived 33% in the last thirty...
New Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 52% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩108.0b market cap, or US$73.0m).
お知らせ • Dec 20Amicogen, Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.000002 billion.Amicogen, Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.000002 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,925,374 Price\Range: KRW 2010
New Risk • Dec 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩143.8b (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩44b free cash flow). Earnings have declined by 52% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩143.8b market cap, or US$97.9m).
New Risk • Nov 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩44b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩44b free cash flow). Earnings have declined by 52% per year over the past 5 years.
分析記事 • Sep 08The Market Doesn't Like What It Sees From Amicogen, Inc.'s (KOSDAQ:092040) Revenues YetWith a price-to-sales (or "P/S") ratio of 1.8x Amicogen, Inc. ( KOSDAQ:092040 ) may be sending very bullish signals at...
お知らせ • Aug 12Amicogen, Inc. announced that it has received KRW 7 billion in funding from BIFIDO Co., Ltd.On August 11, 2025, Amicogen, Inc. closed the transaction.
New Risk • Jul 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 46% per year over the past 5 years.
分析記事 • May 23Amicogen, Inc.'s (KOSDAQ:092040) Share Price Is Matching Sentiment Around Its RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.3x Amicogen, Inc. ( KOSDAQ:092040 ) is definitely a...
Reported Earnings • Mar 25Full year 2024 earnings released: ₩961 loss per share (vs ₩584 loss in FY 2023)Full year 2024 results: ₩961 loss per share (further deteriorated from ₩584 loss in FY 2023). Revenue: ₩173.6b (up 8.6% from FY 2023). Net loss: ₩52.8b (loss widened 127% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 12Amicogen, Inc., Annual General Meeting, Mar 27, 2025Amicogen, Inc., Annual General Meeting, Mar 27, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 33, yeongudanji-ro 55beon-gil, yeonsu-gu, incheon South Korea
分析記事 • Feb 17Is Amicogen (KOSDAQ:092040) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Jan 08Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 35%Amicogen, Inc. ( KOSDAQ:092040 ) shareholders are no doubt pleased to see that the share price has bounced 35% in the...
New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding).
お知らせ • Dec 12An undisclosed buyer agreed to acquire an unknown stake in Amicogen (China) Biopharm Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 54.7 billion.An undisclosed buyer agreed to acquire an unknown stake in Amicogen (China) Biopharm Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 54.7 billion on December 10, 2024. After completion of this ransaction, Amicogen, Inc. will hold 14.36% stake in Amicogen (China) Biopharm. Amicogen (China) Biopharm reported total assets of KRW 210.359 billion, total debt of KRW 95.656 billion, sales of KRW 84.911 billion and net income of KRW 8.074 billion as at September 30, 2024. The expected completion of the transaction is December 30, 2024.
New Risk • Dec 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 3.7% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (40% increase in shares outstanding).
New Risk • Dec 07New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (40% increase in shares outstanding).
お知らせ • Nov 23Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040).Enzynomics Co., Ltd. agreed to acquire 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 5.6 billion on November 15, 2024. A cash consideration of KRW 5.6 billion will be paid by Enzynomics for 2,360,714 shares. For the period ending December 31, 2023, SKINMED Co., Ltd. reported total revenue of KRW 6.07 billion and net loss of KRW 1.04 billion. As of December 31, 2023, SKINMED Co., Ltd. reported total debt of KRW 4.96 billion, total assets of KRW 11.22 billion and total common equity of KRW 6.26 billion. Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) on November 19, 2024.
分析記事 • Nov 11Revenues Working Against Amicogen, Inc.'s (KOSDAQ:092040) Share PriceAmicogen, Inc.'s ( KOSDAQ:092040 ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a strong buy right...
お知らせ • Oct 30+ 1 more updateAmicogen, Inc. announced that it has received KRW 4 billion in funding from Kiwoom Securities Co., Ltd.On October 29, 2024 Amicogen, Inc. closed the transaction.
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding).
分析記事 • Jun 27Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% PoundingTo the annoyance of some shareholders, Amicogen, Inc. ( KOSDAQ:092040 ) shares are down a considerable 27% in the last...
分析記事 • Jun 19Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
分析記事 • Mar 21Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%Amicogen, Inc. ( KOSDAQ:092040 ) shares have had a really impressive month, gaining 39% after a shaky period...
New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (39% increase in shares outstanding).
New Risk • Dec 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 39% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (39% increase in shares outstanding).
New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 44% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).
お知らせ • Jul 19+ 1 more updateAmicogen, Inc. announced that it expects to receive KRW 40 billion in fundingAmicogen, Inc. announced a private placement of series 3 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 40,000,000,000 on July 18, 2022. The bonds will mature on July 20, 2027. The bonds are convertible into 1,622,520 common shares at a price of KRW 24,653 per share. The conversion period is from July 20, 2023 to June 20, 2027. The payment date is July 20, 2022. The transaction has been approved by the board of directors.
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩24,850, the stock trades at a trailing P/E ratio of 14.6x. Average trailing P/E is 33x in the Biotechs industry in South Korea. Total loss to shareholders of 34% over the past three years.
お知らせ • Sep 03Amicogen, Inc. announced that it has received KRW 22.2724863 billion in funding from Lysando AGOn September 2, 2021, Amicogen, Inc. closed the transaction.
お知らせ • Jul 23Amicogen, Inc. (KOSDAQ:A092040) agreed to acquire a 30% stake in BIFIDO Co., Ltd (KOSDAQ:A238200) from a group of shareholders for KRW 60.1 billion.Amicogen, Inc. (KOSDAQ:A092040) agreed to acquire a 30% stake in BIFIDO Co., Ltd (KOSDAQ:A238200) from a group of shareholders for KRW 60.1 billion on July 21, 2021. Under the term, Amicogen will acquire 2.45 million shares of BIFIDO at KRW 24,500 per shares. Amicogen will pay 20% of the consideration amounting to KRW 12.02 billion on July 21, 2021 as the down payment or first payment, second payment or the interim payment which is 30% of the consideration amounting to KRW 18.04 billion will be paid on August 20, 2021 and the balance which is 50% of the consideration amounting to KRW 30.06 billion will be paid on October 20, 2021. Post completion, Amicogen will hold 30% stake in BIFIDO. The transaction was resolved by the board of directors of Amicogen on July 21, 2021. The transaction is expected to close on October 21, 2021.
お知らせ • Jul 15Amicogen, Inc. announced that it expects to receive KRW 22.2724863 billion in funding from Lysando AGAmicogen, Inc. announced a private placement of 532,198 shares at a price of KRW 41,850 per share for gross proceeds of KRW 22,272,486,300 on July 14, 2021. The transaction will include participation from Lysando AG. The transaction is expected to close on August 20, 2021. The securities to be issued will have a hold period of 1 year. The transaction was approved by the board of directors of the company. The company will received funding through third party allocation.
お知らせ • Jul 01Amicogen, Inc. announced that it has received KRW 50 billion in fundingOn June 29, 2021, Amicogen, Inc. closed the transaction.
お知らせ • Jun 24Amicogen, Inc. announced that it expects to receive KRW 50 billion in funding from Samsung Securities Co., Ltd. and other investorsAmicogen, Inc. (KOSDAQ:A092040) announced a private placement of series 1 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 50,000,000,000 on June 23, 2021. The transaction will include participation from Samsung Securities Co., Ltd. (KOSE:A016360) for KRW 46,000,000,000, and Small and Medium Business Banks for the rest. The bonds will mature on June 28, 2026. The bonds are convertible into 1,203,311 common shares at a price of KRW 41,552 per share. The conversion period is from June 29, 2022 to May 29, 2026. The payment date is June 29, 2021. The transaction has been approved by the board.
分析記事 • Mar 23With EPS Growth And More, Amicogen (KOSDAQ:092040) Is InterestingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩36,300, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 54x in the Biotechs industry in South Korea. Total returns to shareholders of 7.7% over the past three years.
分析記事 • Mar 05Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?Amicogen, Inc. ( KOSDAQ:092040 ) shareholders might be concerned after seeing the share price drop 14% in the last...
Is New 90 Day High Low • Feb 24New 90-day low: ₩29,700The company is down 11% from its price of ₩33,400 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.
分析記事 • Feb 15Is Amicogen (KOSDAQ:092040) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Feb 08New 90-day low: ₩31,700The company is down 5.0% from its price of ₩33,300 on 10 November 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period.
分析記事 • Jan 31What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?Every investor in Amicogen, Inc. ( KOSDAQ:092040 ) should be aware of the most powerful shareholder groups...
分析記事 • Jan 14Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?Amicogen (KOSDAQ:092040) has had a rough three months with its share price down 5.7%. However, stock prices are usually...
分析記事 • Dec 30Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...
Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩38,400, the stock is trading at a trailing P/E ratio of 22.1x, up from the previous P/E ratio of 19.2x. This compares to an average P/E of 56x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 68%.
分析記事 • Dec 15Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
分析記事 • Nov 30Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?While Amicogen, Inc. (KOSDAQ:092040) shareholders are probably generally happy, the stock hasn't had particularly good...